Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT_2A receptor the unique player?

ABSTRACT: Major depressive disorder (MDD) is one of the most disabling psychiatric disorders in the world. First-line treatments such as selective serotonin reuptake inhibitors (SSRIs) still have many limitations, including a resistance to treatment in 30% of patients and a delayed clinical benefit that is observed only after several weeks of treatment. Increasing clinical evidence indicates that the acute administration of psychedelic agonists of the serotonin 5-HT_2A receptor (5-HT_2AR), such as psilocybin, to patients with MDD induce fast antidepressant effects, which persist up to five weeks after the treatment. However, the involvement of the 5-HT_2AR in these antidepressant effects remains controversial. Furthermore, whether the hallucinogenic properties of 5-HT

SUBMITTER: Sekssaoui M 

PROVIDER: S-EPMC10876623 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature